Deutsche Bank’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-95,365
| Closed | -$3.84M | – | 3710 |
|
|
2026
Q1 | $3.84M | Sell |
95,365
-1,289,898
| -93% | -$27.8M | ﹤0.01% | 1436 |
|
|
2025
Q4 | $34.8M | Sell |
1,385,263
-119,194
| -8% | -$2.8M | 0.01% | 739 |
|
|
2025
Q3 | $34M | Buy |
1,504,457
+8,161
| +0.5% | +$190K | 0.01% | 708 |
|
|
2025
Q2 | $25.9M | Sell |
1,496,296
-280,280
| -16% | -$5.19M | 0.01% | 764 |
|
|
2025
Q1 | $38.9M | Sell |
1,776,576
-1,801
| -0.1% | -$49.8K | 0.02% | 676 |
|
|
2024
Q4 | $56.7M | Buy |
1,778,377
+30,867
| +2% | +$928K | 0.02% | 611 |
|
|
2024
Q3 | $50.4M | Sell |
1,747,510
-94,532
| -5% | -$3.5M | 0.02% | 599 |
|
|
2024
Q2 | $70.7M | Buy |
1,842,042
+230,269
| +14% | +$10.4M | 0.03% | 460 |
|
|
2024
Q1 | $94.7M | Buy |
1,611,773
+754,774
| +88% | +$48.1M | 0.04% | 369 |
|
|
2023
Q4 | $51.3M | Buy |
856,999
+532,705
| +164% | +$27M | 0.03% | 528 |
|
|
2023
Q3 | $12.3M | Sell |
324,294
-154,072
| -32% | -$6.77M | 0.01% | 821 |
|
|
2023
Q2 | $43.6M | Sell |
478,366
-121,062
| -20% | -$10.4M | 0.02% | 547 |
|
|
2023
Q1 | $39.5M | Buy |
599,428
+336,251
| +128% | +$19.4M | 0.02% | 572 |
|
|
2022
Q4 | $13.6M | Sell |
263,177
-304,568
| -54% | -$16.2M | 0.01% | 864 |
|
|
2022
Q3 | $38.8M | Sell |
567,745
-126,862
| -18% | -$7.51M | 0.02% | 570 |
|
|
2022
Q2 | $31.4M | Buy |
694,607
+150,296
| +28% | +$6.85M | 0.02% | 660 |
|
|
2022
Q1 | $27.7M | Buy |
544,311
+205,558
| +61% | +$9.07M | 0.01% | 752 |
|
|
2021
Q4 | $16M | Buy |
338,753
+47,744
| +16% | +$1.88M | 0.01% | 928 |
|
|
2021
Q3 | $9.59M | Sell |
291,009
-28,952
| -9% | -$1.63M | ﹤0.01% | 1181 |
|
|
2021
Q2 | $20.2M | Sell |
319,961
-99,699
| -24% | -$5.14M | 0.01% | 896 |
|
|
2021
Q1 | $18M | Sell |
419,660
-214,077
| -34% | -$10.1M | 0.01% | 936 |
|
|
2020
Q4 | $36.3M | Buy |
633,737
+76,506
| +14% | +$3.24M | 0.02% | 609 |
|
|
2020
Q3 | $16.8M | Buy |
557,231
+12,144
| +2% | +$363K | 0.01% | 763 |
|
|
2020
Q2 | $17.8M | Buy |
545,087
+359,645
| +194% | +$11.5M | 0.01% | 731 |
|
|
2020
Q1 | $4.97M | Buy |
185,442
+20,432
| +12% | +$725K | ﹤0.01% | 1246 |
|
|
2019
Q4 | $5.05M | Buy |
165,010
+34,247
| +26% | +$948K | ﹤0.01% | 1441 |
|
|
2019
Q3 | $3.15M | Buy |
130,763
+16,399
| +14% | +$451K | ﹤0.01% | 1652 |
|
|
2019
Q2 | $2.9M | Sell |
114,364
-13,152
| -10% | -$268K | ﹤0.01% | 2147 |
|
|
2019
Q1 | $2.48M | Buy |
127,516
+101,431
| +389% | +$1.6M | ﹤0.01% | 2325 |
|
|
2018
Q4 | $343K | Sell |
26,085
-98,833
| -79% | -$1.52M | ﹤0.01% | 3568 |
|
|
2018
Q3 | $2.22M | Buy |
124,918
+54,996
| +79% | +$1.02M | ﹤0.01% | 2788 |
|
|
2018
Q2 | $1.54M | Buy |
69,922
+55,538
| +386% | +$1.28M | ﹤0.01% | 3135 |
|
|
2018
Q1 | $317K | Sell |
14,384
-9,424
| -40% | -$185K | ﹤0.01% | 3957 |
|
|
2017
Q4 | $516K | Buy |
+23,808
| New | +$350K | ﹤0.01% | 3578 |
|
Other funds holding APLS
Deutsche Bank's APLS Position: Q2 2026 in Review
Deutsche Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 95,365 shares — an estimated $3.84M sold.
Deutsche Bank first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $94.7M in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Deutsche Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Deutsche Bank sold 95,365 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.84M.
- Deutsche Bank first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Deutsche Bank's Apellis Pharmaceuticals position peaked at $94.7M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.